AR081331A1 - Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos - Google Patents
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismosInfo
- Publication number
- AR081331A1 AR081331A1 ARP110101386A ARP110101386A AR081331A1 AR 081331 A1 AR081331 A1 AR 081331A1 AR P110101386 A ARP110101386 A AR P110101386A AR P110101386 A ARP110101386 A AR P110101386A AR 081331 A1 AR081331 A1 AR 081331A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- membered
- nrbrc
- ora
- haloalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
También se proporciona una composicion farmacéuticamente aceptable y métodos de uso de los compuestos para preparar medicamentos que modulen la contractilidad muscular esquelética. Reivindicacion 1: Un compuesto de formula (1) o una sal farmacéuticamente aceptable del mismo, en la que R1 se selecciona entre hidrogeno, halogeno, CN, alquilo C1-6, haloalquilo C1-6, C(O)ORa, C(O)NRbRc, ORa, NRbRc, arilo C6-10 y heteroarilo de 5-10 miembros; R2 se selecciona entre cicloalquilo C3-8, cicloalquenilo C3-8, heterocicloalquilo de 3-8 miembros, heterocicloalquenilo de 3-8 miembros, arilo C6-10, heteroarilo de 5-10 miembros y NRbRc, donde cada uno de los grupos cicloalquilo C3-8, cicloalquenilo C3-8, heterocicloalquilo de 3-8 miembros, heterocicloalquenilo de 3-8 miembros, arilo C6-10 y heteroarilo de 5-10 miembros está opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados entre halogeno, CN, oxo, (CH2)nORa, (CH2)nOC(O)Ra, (CH2)nOC(O)ORa, (CH2)nOC(O)NRbRc, (CH2)nNRbRc, (CH2)nNRdC(O)Ra, (CH2)nNRdC(O)ORa, (CH2)nNRdC(O)NRbRc, (CH2)nNRdC(O)C(O)NRbRc, (CH2)nNRdC(S)Ra, (CH2)nNRdC(S)ORa, (CH2)nNRdC(S)NRbRc, (CH2)nNRdC(NRe)NRbRc, (CH2)nNRdS(O)Ra, (CH2)nNRdSO2Ra, (CH2)nNRdSO2NRbRc, (CH2)nC(O)Ra, (CH2)nC(O)ORa, (CH2)nC(O)NRbRc, (CH2)nC(S)Ra, (CH2)nC(S)ORa, (CH2)nC(S)NRbRc, (CH2)nC(NRe)NRbRc, (CH2)nSRa, (CH2)nS(O)Ra, (CH2)nSO2Ra, (CH2)nSO2NRbRc, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, (CH2)ncicloalquilo C3-8, (CH2)nheterocicloaIquiIo de 3-8 miembros, (CH2)narilo C6-10 y (CH2)nheteroarilo de 5-10 miembros, donde cada uno de los grupos alquilo C1-6, alquenilo C2-6, alquinilo C2-6, (CH2)ncicloalquilo C3-8, (CH2)nheterocicloaIquilo de 3-8 miembros, (CH2)narilo C6-10 y (CH2)nheteroarilo de 5-10 miembros está opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes Rf; R3 se selecciona entre hidrogeno, halogeno, CN, alquilo C1-6, haloalquilo C1-6, C(O)ORa, C(O)NRbRc, ORa, NRbRc, arilo C6-10 y heteroarilo de 5-10 miembros; R4 se selecciona entre hidrogeno, alquilo C1-6, haloalquilo C1-6, C(O)Ra, C(O)ORa, C(O)NRbRc y SO2Ra; cada uno de R5 y R6 se selecciona independientemente entre hidrogeno, halogeno, alquilo C1-6 y haloalquilo C1-6; o, como alternativa, R5 y R6 junto con el átomo de carbono al que están unidos forman un grupo seleccionado entre cicloalquilo C3-8, cicloalquenilo C3-8, heterocicloalquilo de 3-8 miembros y heterocicloalquenilo de 3-8 miembros, cada uno opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados entre halogeno, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, S(O)Ra, SO2Ra, SO2NRbRc, alquilo C1-6 y haloalquilo C1-6; R7 se selecciona entre cicloalquilo C3-8, cicloalquenilo C3-8, heterocicloalquilo de 3-8 miembros, heterocicloalquenilo de 3-8 miembros, arilo C6-10 y heteroarilo de 5-10 miembros, cada uno opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados entre halogeno, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, OC(O)NRbRc, NRbRc, NRdC(O)Ra, NRdC(O)ORa, NRdC(O)NRbRc, NRdC(O)C(O)NRbRc, NRdC(S)Ra, NRdC(S)ORa, NRdC(S)NRbRc, NRdC(NRe)NRbRc, NRdS(O)Ra, NRdSO2Ra, NRdSO2NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, C(S)Ra, C(S)ORa, C(S)NRbRc, C(NRe)NRbRc, SRa, S(O)Ra, SO2Ra, SO2NRbRc, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, heterocicloalquilo de 3-8 miembros, heterocicloalquenilo de 3-8 miembros, arilo C6-10, aralquilo C7-11 y heteroarilo de 5-10 miembros, donde cada uno de los grupos alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, heterocicloalquilo de 3-8 miembros, heterocicloalquenilo de 3-8 miembros, arilo C6-10, aralquilo C7-11 y heteroarilo de 5-10 miembros está opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes Rf; cada uno de R8 y R9, en cada caso, se selecciona independientemente entre hidrogeno, halogeno y alquilo C1-6; X se selecciona entre un enlace, -(CH2)p-, -(CH2)pC(O)(CH2)q-, -(CH2)pO(CH2)q-, -(CH2)pS(CH2)q-, -(CH2)pNRd(CH2)q-, -(CH2)pC(O)O(CH2)q-, -(CH2)pOC(O)(CH2)q-, -(CH2)pNRdC(O)(CH2)q-, -(CH2)pC(O)NRd(CH2)q-, -(CH2)pNRdC(O)NRd(CH2)q-, -(CH2)pNRdSO2(CH2)q- y -(CH2)pSO2NRd(CH2)q-; o, como alternativa, X, R2 y R3, junto con los átomos de carbono a los que están unidos, forman un anillo de 5-6 miembros que contiene opcionalmente uno o más heteroátomos seleccionados entre oxígeno, nitrogeno y azufre, y que contiene opcionalmente uno o más dobles enlaces, y opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes Rf; Ra en cada caso, se selecciona independientemente entre hidrogeno, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, heterocicloalquilo de 3-8 miembros, heterocicloalquenilo de 3-8 miembros, arilo C6-10, aralquilo C7-11 y heteroarilo de 5-10 miembros, donde cada uno de los grupos alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, heterocicloalquilo de 3-8 miembros, heterocicloalquenilo de 3-8 miembros, arilo C6-10, aralquilo C7-11 y heteroarilo de 5-10 miembros está opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes Rf; cada uno de Rb y Rc, en cada caso, se selecciona independientemente entre hidrogeno, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, heterocicloalquilo de 3-8 miembros, heterocicloalquenilo de 3-8 miembros, arilo C6-10, aralquilo C7-11, heteroarilo de 5-10 miembros, C(O)Rg, C(O)ORg, C(O)NRiRj y SO2Rg, donde cada uno de los grupos alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, heterocicloalquilo de 3-8 miembros, heterocicloalquenilo de 3-8 miembros, arilo C6-10, aralquilo C7-11 y heteroarilo de 5-10 miembros está opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes Rf; Rd, en cada caso, se selecciona independientemente entre hidrogeno y alquilo C1-6; Re, en cada caso, se selecciona independientemente entre hidrogeno, CN, OH, alcoxi C1-6, alquilo C1-6 y haloalquilo C1-6; Rf, en cada caso, se selecciona independientemente entre halogeno, CN, ORh, OC(O)Rh, OC(O)ORh, OC(O)NRiRj, NRiRj, NRdC(O)Rh, NRdC(O)ORh, NRdC(O)NRiRj, NRdC(O)C(O)NRiRj, NRdC(S)Rh, NRdC(S)ORh, NRdC(S)NRiRj, NRdC(NRe)NRiRj, NRdS(O)Rh, NRdSO2Rh, NRdSO2NRiRj, C(O)Rh, C(O)ORh, C(O)NRiRj, C(S)Rh, C(S)ORh, C(S)NRiRj, C(NRe)NRiRj, SRh, S(O)Rh, SO2Rh, SO2NRiRj, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, heterocicloalquilo de 3-8 miembros, heterocicloalquenilo de 3-8 miembros, arilo C6-10, aralquilo C7-11 y heteroarilo de 5-10 miembros, donde cada uno de los grupos alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, heterocicloalquilo de 3-8 miembros, heterocicloalquenilo de 3-8 miembros, arilo C6-10, aralquilo C7-11 y heteroarilo de 5-10 miembros está opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes Rk; o dos sustituyentes Rf unidos a un solo átomo de carbono, junto con el átomo de carbono al que están unidos, forman un grupo seleccionado entre carbonilo, cicloalquilo C3-8 y heterocicloalquilo de 3-8 miembros; Rg, en cada caso, se selecciona independientemente entre alquilo C1-6, haloalquilo C1-6, fenilo, naftilo y aralquilo C7-11, cada uno opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados entre halogeno, CN, OH, alcoxi C1-6, alquilo C1-6 y haloalquilo C1-6; Rh, en cada caso, se selecciona independientemente entre hidrogeno, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, heterocicloalquilo de 3-8 miembros, heterocicloalquenilo de 3-8 miembros, arilo C6-10, aralquilo C7-11 y heteroarilo de 5-10 miembros, donde cada uno de los grupos alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, heterocicloalquilo de 3-8 miembros, heterocicloalquenilo de 3-8 miembros, arilo C6-10, aralquilo C7-11 y heteroarilo de 5-10 miembros está opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes Rk; cada uno de Ri y Rj, en cada caso, se selecciona independientemente entre hidrogeno, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, heterocicloalquilo de 3-8 miembros, heterocicloalquenilo de 3-8 miembros, arilo C6-10, aralquilo C7-11, heteroarilo de 5-10 miembros, C(O)Rg y C(O)ORg, donde cada uno de los grupos alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, heterocicloalquilo de 3-8 miembros, heterocicloalquenilo de 3-8 miembros, arilo C6-10, aralquilo C7-11 y heteroarilo de 5-10 miembros está opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados entre halogeno, CN, OH, alcoxi C1-6, alquilo C y haloalquilo C1-6; Rk, en cada caso, se selecciona independientemente entre halogeno, CN, OH, alcoxi C1-6, NH2, NH(alquilo C1-6), N(alquilo C1-6)2, NHC(O)alquilo C1-6, NHC(O)aralquilo C7-11, NHC(O)Oalquilo C1-6, NHC(O)Oaralquilo C7-11, OC(O)alquilo C1-6, OC(O)aralquilo C7-11, OC(O)Oalquilo C1-6, OC(O)Oaralquilo C7-11, C(O)alquilo C1-6, C(O)aralquilo C7-11, C(O)Oalquilo C1-6, C(O)Oaralquilo C7-11, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6 y alquinilo C2-6, donde cada sustituyente alquilo C1-6, alquenilo C2-6, alquinilo C2-6 y aralquilo C7-11 está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados entre OH, alcoxi C1-6, NH2, NH(alquilo C1-6), N(alquilo C1-6)2, NHC(O)alquilo C1-6, NHC(O)aralquilo C7-11, NHC(O)Oalquilo C1-6 y NHC(O)Oaralquilo C7-11; o dos sustituyentes Rk unidos a un solo átomo de carbono, junto con el átomo de carbono al que están unidos, forman un grupo carbonilo; m es 0, 1 o 2; n, en cada caso, es independientemente 0, 1 o 2; p es 0, 1 o 2; y q es 0, 1 o 2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32759710P | 2010-04-23 | 2010-04-23 | |
US41229910P | 2010-11-10 | 2010-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR081331A1 true AR081331A1 (es) | 2012-08-08 |
Family
ID=44834530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110101386A AR081331A1 (es) | 2010-04-23 | 2011-04-20 | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
Country Status (34)
Country | Link |
---|---|
US (7) | US8962632B2 (es) |
EP (3) | EP3698795A1 (es) |
JP (1) | JP5852099B2 (es) |
KR (2) | KR101781484B1 (es) |
CN (3) | CN105712974B (es) |
AR (1) | AR081331A1 (es) |
AU (1) | AU2011242575C1 (es) |
BR (1) | BR112012026951B1 (es) |
CA (1) | CA2796637C (es) |
CL (1) | CL2012002944A1 (es) |
CO (1) | CO6620055A2 (es) |
CY (2) | CY1117809T1 (es) |
DK (2) | DK3127540T3 (es) |
EA (2) | EA028079B1 (es) |
EC (1) | ECSP12012293A (es) |
ES (2) | ES2586302T3 (es) |
HK (2) | HK1180604A1 (es) |
HR (2) | HRP20160827T1 (es) |
HU (2) | HUE048815T2 (es) |
IL (2) | IL222467A (es) |
LT (2) | LT3127540T (es) |
ME (2) | ME02439B (es) |
MX (1) | MX2012012189A (es) |
MY (2) | MY193277A (es) |
NZ (1) | NZ603594A (es) |
PH (1) | PH12016502037A1 (es) |
PL (2) | PL2560653T3 (es) |
PT (2) | PT2560653T (es) |
RS (2) | RS60137B1 (es) |
SG (1) | SG184959A1 (es) |
SI (2) | SI3127540T1 (es) |
SM (1) | SMT201600226B (es) |
TW (1) | TWI520737B (es) |
WO (1) | WO2011133888A1 (es) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2942346B1 (en) | 2009-02-17 | 2020-05-06 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as cxcr2 modulators |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
CA2811990C (en) * | 2010-08-23 | 2023-03-21 | Dean Y. Maeda | Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators |
US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
BR112014007310A2 (pt) | 2011-09-27 | 2017-04-04 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante |
EA201491060A1 (ru) * | 2011-11-28 | 2014-09-30 | Новартис Аг | Новые производные трифторметилоксадиазола и их применение для лечения заболевания |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
CA2868507A1 (en) * | 2012-04-02 | 2013-10-10 | Cytokinetics, Inc. | Methods for improving diaphragm function |
SG11201406359TA (en) * | 2012-04-11 | 2014-11-27 | Cytokinetics Inc | Improving resistance to skeletal muscle fatigue |
IL289834B1 (en) | 2012-06-13 | 2024-03-01 | Incyte Holdings Corp | Conversion of tricyclic compounds as FGFR inhibitors |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
EP2970240B1 (en) | 2013-03-14 | 2018-01-10 | Novartis AG | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
SI2986610T1 (en) | 2013-04-19 | 2018-04-30 | Incyte Holdings Corporation | Bicyclic heterocycles as inhibitors of FGFR |
US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
US9783522B2 (en) | 2014-04-24 | 2017-10-10 | Mitsubishi Tanabe Pharma Corporation | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof |
DK3137622T3 (da) | 2014-04-29 | 2022-02-07 | Cytokinetics Inc | Fremgangsmåder til at reducere tilbagegang af vitalkapacitet |
ES2750751T3 (es) * | 2014-09-09 | 2020-03-27 | Astellas Pharma Inc | Composición farmacéutica novedosa para la prevención y/o el tratamiento de la incontinencia urinaria |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
WO2016149160A1 (en) * | 2015-03-15 | 2016-09-22 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
CN105111151B (zh) * | 2015-04-17 | 2018-09-28 | 成都理工大学 | 作为PPAR-γ调节剂的氨基嘧啶衍生物 |
CA2987179C (en) | 2015-05-29 | 2020-08-25 | Pfizer Inc. | Heterocyclic compounds as inhibitors of vanin-1 enzyme |
JP6560436B2 (ja) | 2015-07-27 | 2019-08-14 | チョン クン ダン ファーマシューティカル コーポレーション | ヒストン脱アセチル化酵素6阻害剤としての1,3,4−オキサジアゾールスルホンアミド誘導体化合物及びこれを含有する薬剤学的組成物 |
CA2993918C (en) | 2015-07-27 | 2020-09-29 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same |
PL3328844T3 (pl) | 2015-07-27 | 2020-07-27 | Chong Kun Dang Pharmaceutical Corp. | Pochodne sulfamidu 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i zawierająca je kompozycja farmaceutyczna |
ES2903214T3 (es) | 2015-08-04 | 2022-03-31 | Chong Kun Dang Pharmaceutical Corp | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de la histona desacetilasa 6 y la composición farmacéutica que comprende los mismos |
DK3362445T3 (da) * | 2015-10-12 | 2023-02-27 | Chong Kun Dang Pharmaceutical Corp | Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed |
HUE058820T2 (hu) | 2016-02-12 | 2022-09-28 | Cytokinetics Inc | Tetrahidroizokinolin származékok |
SG11201811161YA (en) | 2016-07-14 | 2019-01-30 | Pfizer | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
WO2018165520A1 (en) * | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
KR101798840B1 (ko) * | 2017-05-17 | 2017-11-17 | 주식회사 레고켐 바이오사이언스 | 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물 |
US10961242B2 (en) | 2017-05-17 | 2021-03-30 | Legochem Biosciences, Inc. | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
SG10202002990XA (en) | 2017-08-04 | 2020-05-28 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
US11547712B2 (en) | 2017-11-20 | 2023-01-10 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
CA3087051A1 (en) * | 2017-12-26 | 2019-07-04 | Cytokinetics, Incorporated | Process for the preparation of an amino-pyrimidine and intermediates thereof |
WO2019134661A1 (zh) * | 2018-01-03 | 2019-07-11 | 南京明德新药研发股份有限公司 | 异吲哚啉酮及其衍生物作为csf-1r抑制剂 |
AU2019205944A1 (en) | 2018-01-05 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
JP2021518413A (ja) | 2018-03-20 | 2021-08-02 | アイカーン スクール オブ メディシン アット マウント サイナイ | キナーゼ阻害剤化合物及び組成物ならびに使用方法 |
MX2020011639A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr). |
EP3788047A2 (en) | 2018-05-04 | 2021-03-10 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
CN110483440A (zh) * | 2018-06-11 | 2019-11-22 | 上海睿升化工科技有限公司 | 一种2-(2-溴-1,3-噻唑-5-基)乙腈的制备方法 |
KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
EP3877367A1 (en) | 2018-11-06 | 2021-09-15 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
BR112021008905A2 (pt) | 2018-11-06 | 2021-08-10 | Edgewise Therapeutics, Inc. | compostos de piridazinona e usos dos mesmos |
US20220064146A1 (en) * | 2018-12-31 | 2022-03-03 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
JP2022521467A (ja) | 2019-02-05 | 2022-04-08 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11090278B2 (en) | 2019-05-16 | 2021-08-17 | Nexus Pharmaceuticals, Inc. | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
KR20220079512A (ko) * | 2019-06-27 | 2022-06-13 | 싸이토키네틱스, 인코포레이티드 | 1-(2-((((트랜스)-3-플루오로-1-(3-플루오로피리딘-2-일)시클로부틸)메틸)아미노)피리미딘-5-일)-1h-피르롤-3-카르복사미드의 다형체들 |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
BR112022007163A2 (pt) | 2019-10-14 | 2022-08-23 | Incyte Corp | Heterociclos bicíclicos como inibidores de fgfr |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
JP2023526247A (ja) * | 2020-05-13 | 2023-06-21 | エッジワイズ セラピューティクス, インコーポレイテッド | 神経筋疾患の処置のためのピリダジノン化合物 |
WO2021231565A1 (en) * | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
EP4182030A1 (en) * | 2020-07-15 | 2023-05-24 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
GB2598768A (en) * | 2020-09-11 | 2022-03-16 | Moa Tech Limited | Herbicidal heterocyclic derivatives |
JP2023547892A (ja) * | 2020-10-27 | 2023-11-14 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 5-ht2aセロトニン受容体に関連する障害を処置するために有用な5-ht2aセロトニン受容体のモジュレーターとしてのピリミジン誘導体 |
EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
WO2024064745A1 (en) | 2022-09-21 | 2024-03-28 | Cytokinetics, Incorporated | Synthesis of reldesemtiv |
Family Cites Families (263)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB284425A (en) | 1926-11-22 | 1928-02-02 | James Last | Improvements in and relating to sand or like moulds for making castings |
CH361573A (de) * | 1957-07-12 | 1962-04-30 | Cilag Chemie Aktiengesellschaf | Verfahren zur Herstellung neuer 5-Aminomethyl-pyrimidine |
US3239345A (en) | 1965-02-15 | 1966-03-08 | Estrogenic compounds and animal growth promoters | |
JPS5416487B1 (es) | 1970-03-17 | 1979-06-22 | ||
US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
GB1345880A (en) | 1971-06-18 | 1974-02-06 | Cepbepe | Pyridazine derivatives |
US4036979A (en) | 1974-01-25 | 1977-07-19 | American Cyanamid Company | Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate |
US4157392A (en) | 1977-05-17 | 1979-06-05 | Diamond Shamrock Corporation | Pharmacologically active substituted 1,2,4-triazines |
HU175471B (hu) | 1977-06-13 | 1980-08-28 | Gyogyszerkutato Intezet | Sposob poluchenija novykh proizvodnykh 3-skobka-1-pirazolil-skobka zakryta-piridazina |
DE2730467A1 (de) * | 1977-07-06 | 1979-01-18 | Basf Ag | Benzylpyrimidine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
FR2510997A1 (fr) | 1981-08-10 | 1983-02-11 | Sanofi Sa | Nouveaux derives de la methyl-4 phenyl-6 pyridazine, procede pour leur preparation et medicaments actifs sur le systeme nerveux central en contenant |
FR2540115B1 (fr) | 1983-01-28 | 1985-06-07 | Sanofi Sa | Derive de la pyridazine ayant une action psychotrope, son mode de preparation et les medicaments en contenant |
US4565814A (en) | 1983-01-28 | 1986-01-21 | Sanofi | Pyridazine derivatives having a psychotropic action and compositions |
EP0254259A3 (en) | 1986-07-21 | 1989-11-23 | Otsuka Pharmaceutical Factory, Inc. | P-aminophenol derivatives |
JPS63165376A (ja) | 1986-12-27 | 1988-07-08 | Nippon Soda Co Ltd | オキサ(チア)ジアゾ−ル誘導体その製造方法及び殺ダニ剤 |
CN1027537C (zh) | 1987-06-25 | 1995-02-01 | 伊莱利利公司 | 制备除草和杀虫的尿素类的新方法 |
JPH03502329A (ja) | 1988-01-28 | 1991-05-30 | ポリゲン ホールディング コーポレイション | 成長ホルモン放出活性を有するポリペプチド化合物類 |
AU628322B2 (en) | 1988-01-28 | 1992-09-17 | Eastman Kodak Company | Polypeptide compounds having growth hormone releasing activity |
JPH01261381A (ja) | 1988-04-12 | 1989-10-18 | Nippon Soda Co Ltd | オキサ(チア)ジアゾール誘導体、その製造方法及び殺ダニ剤 |
FR2636628B1 (fr) | 1988-08-25 | 1990-12-28 | Sanofi Sa | Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant |
JPH02164863A (ja) | 1988-12-15 | 1990-06-25 | Otsuka Pharmaceut Co Ltd | p−アミノフェノール誘導体の製造方法 |
US5461053A (en) | 1989-02-07 | 1995-10-24 | Sanofi | Pyridazine derivatives |
FR2663326B2 (fr) | 1989-11-17 | 1992-10-16 | Sanofi Sa | Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant. |
US5631255A (en) | 1989-02-07 | 1997-05-20 | Sanofi | Pyridazine derivatives |
GR900100380A (el) | 1989-05-20 | 1991-10-10 | Fisons Plc | Μέ?οδος παρασκευής αντι-φλεγμονωδών παραγώγων αμινοφενόλης. |
IL96891A0 (en) | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
GB9008123D0 (en) | 1990-04-10 | 1990-06-06 | Lilly Industries Ltd | Pharmaceutical compounds |
US5208248A (en) | 1991-01-11 | 1993-05-04 | Merck Sharpe & Dohme, Ltd. | Indazole-substituted five-membered heteroaromatic compounds |
US5317103A (en) | 1991-01-15 | 1994-05-31 | Merck Sharp & Dohme Limited | Indole-substituted five-membered heteroaromatic compounds as 5-HT1 agonists |
JP2651755B2 (ja) | 1991-03-01 | 1997-09-10 | 富士写真フイルム株式会社 | ハロゲン化銀カラー写真感光材料 |
WO1992016527A1 (en) | 1991-03-22 | 1992-10-01 | Nippon Soda Co., Ltd. | 2-substituted pyridine derivative, production thereof, and agrohorticultural bactericide |
US5114958A (en) | 1991-05-09 | 1992-05-19 | Warner-Lambert Company | 1,2,4-oxadiazole and 1,2,4-thiadiazole derivatives of fenamates as antiinflammatory agents |
FR2676444B1 (fr) | 1991-05-16 | 1995-03-10 | Sanofi Elf | Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant. |
JPH06509574A (ja) | 1991-08-03 | 1994-10-27 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5−ht↓4レセプターアンタゴニスト |
US5663146A (en) | 1991-08-22 | 1997-09-02 | Administrators Of The Tulane Educational Fund | Polypeptide analogues having growth hormone releasing activity |
JPH05117255A (ja) | 1991-10-25 | 1993-05-14 | Nippon Soda Co Ltd | オキサジアゾール及びチアジアゾール誘導体、その製法 |
JPH07500116A (ja) | 1992-03-26 | 1995-01-05 | ダウエランコ | 殺菌剤としてのn−複素環式ニトロアニリン |
US5654322A (en) | 1992-08-11 | 1997-08-05 | Wakunaga Seiyaku Kabushiki Kaisha | Biphenylmethane derivatives and pharmaceuticals containing the same |
WO1994028898A1 (en) | 1993-06-15 | 1994-12-22 | Pfizer Inc. | H2-antagonists as immune stimulants in bacterial infections of cattle or swine |
ZW8594A1 (en) | 1993-08-11 | 1994-10-12 | Bayer Ag | Substituted azadioxacycbalkenes |
DE4331178A1 (de) * | 1993-09-14 | 1995-03-16 | Hoechst Schering Agrevo Gmbh | Substituierte Pyridine und Pyrimidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
DE4424788A1 (de) | 1993-12-22 | 1995-06-29 | Bayer Ag | Arylessigsäurederivate |
US6008257A (en) | 1994-01-28 | 1999-12-28 | Bayer Aktiengesellschaft | Hydroxamic-acid derivatives, method of preparing them and their use as fungicides |
GB9405347D0 (en) * | 1994-03-18 | 1994-05-04 | Agrevo Uk Ltd | Fungicides |
DE69535592T2 (de) | 1994-03-25 | 2008-06-12 | Isotechnika, Inc., Edmonton | Verbesserung der effektivität von arzneimitteln duren deuterierung |
US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5922751A (en) | 1994-06-24 | 1999-07-13 | Euro-Celtique, S.A. | Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same |
PT779884E (pt) | 1994-09-09 | 2000-10-31 | Bayer Ag | Derivados de imidoacidos e sua utilizacao como pesticidas |
US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US6096895A (en) | 1995-05-17 | 2000-08-01 | E. I. Du Pont De Nemours And Company | Heterocyclic dihydrazole compounds and their use for controlling fungal plant diseases |
TW502026B (en) | 1995-06-20 | 2002-09-11 | Zeneca Ltd | Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates |
TW434240B (en) | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
KR19990028230A (ko) | 1995-06-20 | 1999-04-15 | 미리암 디. 메코너헤이 | 살절지동물성 및 살진균성 시클릭 아미드 |
US5834468A (en) | 1995-07-07 | 1998-11-10 | Zeneca Limited | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists |
DE19525969A1 (de) | 1995-07-17 | 1997-01-23 | Bayer Ag | Etherderivate |
US20070173465A9 (en) | 1995-10-11 | 2007-07-26 | Monahan Sean D | Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene |
CN1056370C (zh) | 1995-10-17 | 2000-09-13 | 化学工业部沈阳化工研究院 | 具有除草活性的4-芳氧(硫或氨)基嘧啶衍生物及其制备 |
US5729399A (en) | 1995-12-13 | 1998-03-17 | International Business Machines Corporation | Contact start/stop disk drive with minimized head-disk wear in textured landing zone |
EP0873361B1 (en) | 1995-12-13 | 2006-11-02 | The Regents Of The University Of California | Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand |
US6114537A (en) | 1996-02-26 | 2000-09-05 | Apotex Inc. | Process for scavenging thiols |
US5874452A (en) | 1996-04-03 | 1999-02-23 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5854265A (en) | 1996-04-03 | 1998-12-29 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
JP2000507592A (ja) | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質トランスフェラーゼ阻害剤 |
CA2249639A1 (en) | 1996-04-03 | 1997-10-09 | Neville J. Anthony | Inhibitors of farnesyl-protein transferase |
EP0891357A1 (en) | 1996-04-03 | 1999-01-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CA2250204A1 (en) | 1996-04-03 | 1997-10-09 | Neville J. Anthony | Inhibitors of farnesyl-protein transferase |
US5859035A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
TW414795B (en) | 1996-07-01 | 2000-12-11 | Yamanouchi Pharma Co Ltd | A thiophene derivative and the pharmaceutical composition |
BR9711816A (pt) | 1996-08-01 | 1999-08-31 | Du Pont | Composto, composição fungicida, método para controlar doenças de plantas causadas pelos agentes patogênicos f·ngicos de plantas, composição artropodicida e método para controlar artrópodes. |
WO1998023155A1 (en) | 1996-11-26 | 1998-06-04 | E.I. Du Pont De Nemours And Company | Arthropodicidal and fungicidal cyclic amides |
US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
US5939439A (en) | 1996-12-30 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
HRP980093A2 (en) | 1997-02-28 | 1998-12-31 | Lilly Co Eli | Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting "beta"-amyloid peptide release and/or its synthesis by use of such compounds |
US6699853B2 (en) | 1997-06-16 | 2004-03-02 | Hoechst Schering Agrevo Gmbh | 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines, processes for their preparation, compositions comprising them, and their use as pesticides |
DE19725450A1 (de) | 1997-06-16 | 1998-12-17 | Hoechst Schering Agrevo Gmbh | 4-Haloalkyl-3-heterocyclylpyridine und 4-Haloalkyl-5-heterocyclylpyrimidine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel |
GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
GB9716446D0 (en) | 1997-08-05 | 1997-10-08 | Agrevo Uk Ltd | Fungicides |
WO1999042455A1 (en) | 1998-02-19 | 1999-08-26 | Tularik Inc. | Antiviral agents |
US6506782B1 (en) | 1998-02-27 | 2003-01-14 | Athena Neurosciences, Inc. | Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
DE19824175A1 (de) | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino-azol-Verbindungen |
PL346247A1 (en) | 1998-08-18 | 2002-01-28 | Ucb Sa | Muscarinic agonists and antagonists |
WO2000024725A1 (en) | 1998-10-26 | 2000-05-04 | Vertex Pharmaceuticals Incorporated | Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase |
EP1126833A4 (en) | 1998-10-29 | 2004-09-08 | Trega Biosciences Inc | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES |
US20040053900A1 (en) | 1998-12-23 | 2004-03-18 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy |
GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
EP1394150B1 (en) | 1999-02-24 | 2011-01-19 | F. Hoffmann-La Roche AG | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
JP2000281579A (ja) | 1999-03-29 | 2000-10-10 | Sumitomo Pharmaceut Co Ltd | オキサジアゾリル−1,4−ジヒドロピリジン誘導体を含有するプロテオグリカン生成促進剤 |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
US6410254B1 (en) | 1999-05-18 | 2002-06-25 | Cytokinetics | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
US7202051B1 (en) | 1999-05-18 | 2007-04-10 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
US6743599B1 (en) | 1999-05-18 | 2004-06-01 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
EP1206935A4 (en) | 1999-07-23 | 2008-07-30 | Shionogi & Co | TH2 DIFFERENTIAL INHIBITION |
AU6994600A (en) | 1999-08-12 | 2001-03-13 | Basf Aktiengesellschaft | Substituted benzoxazoles |
EP1078632A1 (en) | 1999-08-16 | 2001-02-28 | Sanofi-Synthelabo | Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity |
JP4144978B2 (ja) | 1999-09-09 | 2008-09-03 | 富士フイルム株式会社 | 1,2,4−チアジアゾール誘導体の合成法 |
US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
WO2001021160A2 (en) | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Carboxymide and aniline derivatives as selective inhibitors of pathogens |
GB9927844D0 (en) * | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
CA2388529A1 (en) | 1999-11-29 | 2001-06-07 | Pierre Ducray | Pesticidal n-heteroaryl alpha-alkoximino-carboxamides |
PT1254135E (pt) | 1999-12-02 | 2005-03-31 | Novartis Ag | Compostos organicos |
US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
AU2010601A (en) | 1999-12-16 | 2001-07-03 | Novartis Ag | Organic compounds |
TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
US20020002171A1 (en) | 2000-01-28 | 2002-01-03 | Chalquest Richard R. | Materials and methods for killing nematodes and nematode eggs |
DE10006453A1 (de) | 2000-02-14 | 2001-08-16 | Bayer Ag | Piperidylcarbonsäuren als Integrinantagonisten |
US7078536B2 (en) | 2001-03-14 | 2006-07-18 | Genesoft Pharmaceuticals, Inc. | Charged compounds comprising a nucleic acid binding moiety and uses therefor |
MXPA02009763A (es) | 2000-04-04 | 2003-03-27 | Shionogi & Co | Composiciones aceitosas las cuales contienen farmacos altamente solubles en grasa. |
AU2001244610A1 (en) | 2000-04-05 | 2001-10-23 | Shionogi And Co., Ltd. | Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof |
US6552033B1 (en) | 2000-05-16 | 2003-04-22 | The Procter & Gamble Co. | Imidazo-containing heterocyclic compounds, their compositions and uses |
GB0012671D0 (en) * | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
AU2001268711A1 (en) | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
CA2410393A1 (en) | 2000-06-23 | 2002-01-03 | Dupont Pharmaceuticals Company | 1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor xa inhibitors |
PE20020384A1 (es) | 2000-07-21 | 2002-05-28 | Schering Corp | PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C |
EP1178035B1 (en) | 2000-08-04 | 2008-07-30 | Bayer CropScience S.A. | Fungicidal phenylimine derivatives |
EP1180512A1 (en) | 2000-08-04 | 2002-02-20 | Aventis Cropscience S.A. | Fungicidal phenylimine derivatives |
EP1178036A1 (en) | 2000-08-04 | 2002-02-06 | Aventis Cropscience S.A. | Fungicidal phenylimidate derivatives |
FR2812633A1 (fr) | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
AU2002214626A1 (en) | 2000-09-29 | 2002-04-08 | Cor Therapeutics, Inc. | Quaternary amines and related inhibitors of factor xa |
US6667326B1 (en) | 2000-11-16 | 2003-12-23 | Novartis Animal Health Us, Inc. | Pesticidal aminoheterocyclamide compounds |
AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
JP2002212169A (ja) | 2001-01-12 | 2002-07-31 | Sumitomo Pharmaceut Co Ltd | 5員複素芳香環化合物 |
CA2435143A1 (en) | 2001-01-26 | 2002-08-01 | Shionogi & Co., Ltd. | Halogen compounds having thrombopoietin receptor agonism |
EP1361220A4 (en) | 2001-01-26 | 2005-09-07 | Shionogi & Co | CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM |
JP4175113B2 (ja) | 2001-03-14 | 2008-11-05 | 小野薬品工業株式会社 | Ep1アンタゴニストを有効成分として含有するうつ病の治療剤 |
US6960595B2 (en) | 2001-03-23 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | 5-6 to 5-7 Heterobicycles as factor Xa inhibitors |
JP2002305083A (ja) | 2001-04-04 | 2002-10-18 | Mitsubishi Chemicals Corp | 有機電界発光素子 |
RU2003138074A (ru) | 2001-06-08 | 2005-02-20 | Цитови Инк. (US) | Замещенные 3-арил-5-арил-[1,2,4]-оксадиазолы и их аналоги в качестве активаторов каспаз и индукторов апоптоза, а также их применение |
TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
US6825221B2 (en) | 2001-10-18 | 2004-11-30 | Allergan, Inc. | Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain |
US6921762B2 (en) | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
AU2002354056A1 (en) | 2001-11-19 | 2003-06-10 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary frequency |
US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
US20040110757A1 (en) | 2002-03-21 | 2004-06-10 | Thomas Arrhenius | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis |
AU2003222648A1 (en) | 2002-05-13 | 2003-12-02 | Eli Lilly And Company | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
US7119111B2 (en) | 2002-05-29 | 2006-10-10 | Amgen, Inc. | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use |
US7232616B2 (en) | 2002-06-13 | 2007-06-19 | Tsinghua University | Organic electroluminescent materials and devices made from such materials |
CA2489458A1 (en) * | 2002-06-14 | 2003-12-24 | Altana Pharma Ag | Substituted diaminopyrimidines |
ES2373226T3 (es) * | 2002-06-28 | 2012-02-01 | Astellas Pharma Inc. | Derivado de diaminopirimidincarboxamida. |
DK1539724T3 (da) | 2002-08-07 | 2008-02-11 | Neuraxon Inc | Aminobenzothiazolforbindelser med NOS-inhiberende aktivitet |
IL166510A0 (en) | 2002-08-09 | 2006-01-15 | Nps Pharma Inc | 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5 |
EP1537116B1 (en) * | 2002-09-04 | 2010-06-02 | Schering Corporation | Pyrazolopyrimidines suitable for the treatment of cancer diseases |
AU2003266668A1 (en) | 2002-09-30 | 2004-04-23 | Banyu Pharmaceutical Co., Ltd. | 2-aminobenzimidazole derivative |
JP4688498B2 (ja) | 2002-11-04 | 2011-05-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | Jakインヒビターとしてのヘテロアリール−ピリミジン誘導体 |
BR0316191A (pt) | 2002-11-11 | 2005-09-27 | Bayer Healthcare Ag | Derivados de amino alcano de fenila ou heteroarila como antagonistas de receptor de ip |
CA2507699A1 (en) | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
US20040147561A1 (en) | 2002-12-27 | 2004-07-29 | Wenge Zhong | Pyrid-2-one derivatives and methods of use |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
TW200418835A (en) | 2003-01-24 | 2004-10-01 | Tanabe Seiyaku Co | A pyrazolopyrimidine compound and a process for preparing the same |
CN100345853C (zh) | 2003-01-24 | 2007-10-31 | 田边制药株式会社 | 吡唑并嘧啶化合物及其制备方法 |
AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
US7157455B2 (en) * | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
JP2006523184A (ja) | 2003-02-22 | 2006-10-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 液晶としてのシアノピリドン誘導体 |
US20050187266A1 (en) | 2003-04-15 | 2005-08-25 | Pfizer Inc | Alpha substituted carboxylic acids |
PL1635824T3 (pl) | 2003-06-03 | 2010-01-29 | Novartis Ag | 5-Członowe heterocykliczne inhibitory P-38 |
US20050004133A1 (en) | 2003-06-05 | 2005-01-06 | Makings Lewis R. | Modulators of VR1 receptor |
PT1354876E (pt) | 2003-06-13 | 2005-06-30 | Servier Lab | Novo processo de sintese do acido (2s,3as,7as)-per-hidroindole-2-carboxilico e dos seus esteres e aplicacao a sintese do perindopril |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
CA2532800C (en) * | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
JP2007512230A (ja) | 2003-08-20 | 2007-05-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用な(4−アミノ−1,2,5−オキサジアゾール−4−イル)−ヘテロ芳香族化合物 |
US7378409B2 (en) | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
EP2609919A3 (en) | 2003-09-26 | 2014-02-26 | Exelixis, Inc. | c-Met modulators and methods of use |
TWI316955B (en) | 2003-11-19 | 2009-11-11 | Chisso Corp | Photo-polymerization liquid composition,polymer or polymer co mposition and optical compensation device thereof |
WO2005051932A1 (ja) | 2003-11-28 | 2005-06-09 | Nippon Soda Co., Ltd. | アリール複素環誘導体および農園芸用殺菌剤および殺虫剤 |
GB0328295D0 (en) | 2003-12-05 | 2004-01-07 | Muscagen Ltd | Therapeutic compounds |
US20070191336A1 (en) | 2003-12-24 | 2007-08-16 | Flynn Daniel L | Anti-inflammatory medicaments |
US7319108B2 (en) | 2004-01-25 | 2008-01-15 | Sanofi-Aventis Deutschland Gmbh | Aryl-substituted heterocycles, process for their preparation and their use as medicaments |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
CN1918128B (zh) | 2004-02-13 | 2011-01-26 | 万有制药株式会社 | 稠环4-氧代-嘧啶衍生物 |
US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
DE102004008141A1 (de) | 2004-02-19 | 2005-09-01 | Abbott Gmbh & Co. Kg | Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren |
AU2005225471B2 (en) * | 2004-03-26 | 2011-05-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
JPWO2005095364A1 (ja) | 2004-03-30 | 2008-02-21 | 第一三共株式会社 | フェノキシ酢酸誘導体及びそれを用いた医薬 |
EP1749827A4 (en) | 2004-03-30 | 2010-04-21 | Kyowa Hakko Kirin Co Ltd | ANTITUMOR AGENTS |
US7423147B2 (en) | 2004-03-31 | 2008-09-09 | Janssen Pharmaceutical, N.V. | Pyridine compounds as histamine H3 modulators |
AU2005231375A1 (en) | 2004-03-31 | 2005-10-20 | Janssen Pharmaceutica, N.V. | Non-imidazole heterocyclic compounds as histamine H3 receptor modulators |
CN101014597A (zh) | 2004-04-02 | 2007-08-08 | 沃泰克斯药物股份有限公司 | 可用作rock和其他蛋白激酶抑制剂的吖吲哚 |
US7439369B2 (en) | 2004-06-22 | 2008-10-21 | Loa Alamos National Security, Llc | Method and system for hydrogen evolution and storage |
CA2577061C (en) | 2004-08-23 | 2014-02-18 | Eli Lilly And Company | Histamine h3 receptor agents, preparation and therapeutic uses |
US7718801B2 (en) | 2004-08-31 | 2010-05-18 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazole derivative |
EP2592075B1 (en) | 2004-11-02 | 2015-04-29 | Northwestern University | Pyridazine compounds for the treatment of inflammatory diseases |
EP1809290A2 (en) * | 2004-11-03 | 2007-07-25 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as ion channel modulators and methods of use |
JP2008520738A (ja) | 2004-11-22 | 2008-06-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼの阻害剤として有用なピロロピラジンおよびピラゾロピラジン |
ES2450566T3 (es) * | 2004-11-30 | 2014-03-25 | Amgen Inc. | Análogos de quinazolina y quinolinas y su uso como medicamentos para tratar el cáncer |
US20070123572A1 (en) | 2005-11-28 | 2007-05-31 | Kalypsys, Inc. | Novel method of preparation of 5-chloro-3-imidazol-1-yl-[1,2,4]thiadiazole and (3-imidazol-1-yl-[1,2,4]thiadiazol-5yl)-dialkyl-amines |
CA2590939C (en) * | 2004-12-17 | 2011-10-18 | Amgen Inc. | Aminopyrimidine compounds and methods of use |
JP2008526777A (ja) | 2005-01-05 | 2008-07-24 | ライジェル ファーマシューティカルズ, インコーポレイテッド | ユビキチンリガーゼインヒビター |
ATE499370T1 (de) | 2005-01-19 | 2011-03-15 | Bristol Myers Squibb Co | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3- aminderivate und verwandte verbindungen als p2y1- rezeptor-hemmer zur behandlung thromboembolischer erkrankungen |
WO2006081388A2 (en) | 2005-01-25 | 2006-08-03 | Neurogen Corporation | Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues |
ATE451363T1 (de) | 2005-01-26 | 2009-12-15 | Schering Corp | 3-(indazol-5-yl)-(1,2,4)triazinderivate und verwandte verbindungen als proteinkinaseinhibitoren zur behandlung von krebs |
AU2006210513C1 (en) | 2005-02-04 | 2012-10-25 | Senomyx, Inc. | Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions |
DE602006001515D1 (de) | 2005-02-16 | 2008-07-31 | Astrazeneca Ab | Chemische verbindungen |
JP2006274133A (ja) | 2005-03-30 | 2006-10-12 | Fuji Photo Film Co Ltd | 液晶組成物、位相差板及び楕円偏光板 |
WO2006108059A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
MX2007015427A (es) | 2005-06-07 | 2008-04-16 | Pharmacopeia Inc | Inhibidores de azinona y diazinona v3 para depresion y trastornos de estres. |
EP2233470B1 (en) | 2005-07-04 | 2011-12-07 | High Point Pharmaceuticals, LLC | Histamine H3 receptor antagonists |
WO2007012642A1 (de) | 2005-07-29 | 2007-02-01 | Basf Aktiengesellschaft | 7-amino-6-thiadiazolyl- und -oxadiazolyl- 1 , 2 , 4-triazolo [1 , 5 -a] pyrimidin- verbindungen und ihre verwendung zur bekämpfung von schadpilzen |
US7345178B2 (en) | 2005-08-04 | 2008-03-18 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
RU2008110949A (ru) | 2005-08-23 | 2009-09-27 | Айрм Ллк (Bm) | Соединения и композиции-иммуносупрессанты |
JP2007093918A (ja) | 2005-09-28 | 2007-04-12 | Fujifilm Corp | 光学ローパスフィルター、およびその製造方法 |
JP2007093919A (ja) | 2005-09-28 | 2007-04-12 | Fujifilm Corp | 光学ローパスフィルター、およびその製造方法 |
WO2007037010A1 (ja) | 2005-09-29 | 2007-04-05 | Daiichi Pharmaceutical Co., Ltd. | フェノキシ酢酸誘導体及びそれを用いた医薬 |
US7531482B2 (en) | 2005-10-21 | 2009-05-12 | Dow Agrosciences Llc | Thieno-pyrimidine compounds having fungicidal activity |
JP5243960B2 (ja) | 2005-10-21 | 2013-07-24 | ダウ アグロサイエンシィズ エルエルシー | 殺菌活性を有するチエノ−ピリミジン化合物 |
AU2006307953A1 (en) | 2005-10-26 | 2007-05-03 | Boehringer Ingelheim International Gmbh | (Hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds |
DK2404919T3 (da) | 2005-11-08 | 2013-11-04 | Vertex Pharma | Heterocyclisk forbindelse, der er egnet som modulator af ATP-bindende kassettetransportører |
ES2700433T3 (es) | 2005-12-13 | 2019-02-15 | Incyte Holdings Corp | Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas Janus |
US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
US20070197505A1 (en) * | 2005-12-15 | 2007-08-23 | Morgan Bradley P | Certain chemical entities, compositions and methods |
US7718657B2 (en) | 2005-12-16 | 2010-05-18 | Cytokinetics, Inc. | Certain indanyl urea modulators of the cardiac sarcomere |
WO2007075896A2 (en) | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
WO2007076460A2 (en) | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Substituted thiazole ureas useful as inhibitors of protein kinases |
US7951803B2 (en) | 2006-03-09 | 2011-05-31 | Pharmacopeia, Llc | 8-heteroarylpurine MNK2 inhibitors for treating metabolic disorders |
JP5243696B2 (ja) | 2006-03-17 | 2013-07-24 | 田辺三菱製薬株式会社 | ベンゼン誘導体 |
SI2007752T1 (sl) | 2006-03-31 | 2010-12-31 | Janssen Pharmaceutica Nv | Benzoimidazol-2-il pirimidini in pirazini kot modulatorji histamin H4 receptorja |
KR101464385B1 (ko) | 2006-04-19 | 2014-11-21 | 노파르티스 아게 | 6-o-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 csf-1r 신호전달의 억제 방법 |
AU2007240860A1 (en) | 2006-04-19 | 2007-11-01 | Merck Serono Sa | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors |
MX2008013511A (es) | 2006-04-28 | 2008-10-28 | Shionogi & Co | Derivados de amina que tienen actividad antagonista del receptor neuropeptido y y5. |
WO2007127475A2 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Pyridazines for demyelinating diseases and neuropathic pain |
WO2007130383A2 (en) | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
EP2035005A4 (en) | 2006-06-09 | 2011-07-06 | Kemia Inc | THERAPY BASED ON CYTOKINE INHIBITORS |
US8435774B2 (en) | 2006-06-28 | 2013-05-07 | Qiagen Gmbh | Enhancing reactivation of thermostable reversibly inactivated enzymes |
AU2007271089A1 (en) | 2006-07-07 | 2008-01-10 | Boehringer Ingelheim International Gmbh | Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumor agents |
WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
CA2660699A1 (en) * | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyridine compounds for treating gpr119 related disorders |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
WO2008071646A1 (en) | 2006-12-11 | 2008-06-19 | Boehringer Ingelheim International Gmbh | New pyridazine derivatives with mch antagonistic activity and medicaments comprising these compounds |
DE102007002717A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
WO2009011285A1 (ja) * | 2007-07-13 | 2009-01-22 | Taisho Pharmaceutical Co., Ltd. | ヘテロアリールベンゼン化合物 |
GB0720444D0 (en) | 2007-10-18 | 2007-11-28 | Glaxo Group Ltd | Novel compounds |
US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
TW200940537A (en) | 2008-02-26 | 2009-10-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
WO2009131958A2 (en) | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising triazine derivatives |
WO2009131947A2 (en) | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyridazine derivatives |
UY31865A (es) | 2008-06-04 | 2010-01-29 | Astrazeneca Ab | Derivados de urea heterocíclicos y métodos para la utilización de los mismos |
US8183267B2 (en) | 2008-06-09 | 2012-05-22 | Awd. Pharma Gmbh & Co. Kg | Carboxylic acid salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine |
MX2011000081A (es) * | 2008-06-30 | 2011-03-02 | Janssen Pharmaceutica Nv | Proceso para la preparacion de derivados de benzoimidazol-2-il pirimidina. |
US20100025641A1 (en) | 2008-08-04 | 2010-02-04 | Fujifilm Corporation | Infrared region selective reflection coat and infrared region selective reflection film |
EP2326627A1 (en) * | 2008-08-20 | 2011-06-01 | Schering Corporation | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
JP2010132590A (ja) | 2008-12-03 | 2010-06-17 | Astellas Pharma Inc | オキサジアゾール化合物 |
KR20120002581A (ko) | 2009-03-30 | 2012-01-06 | 아스텔라스세이야쿠 가부시키가이샤 | 피리미딘 화합물 |
WO2011032169A2 (en) | 2009-09-14 | 2011-03-17 | Phusis Therapeutics Inc. | Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
NZ611529A (en) | 2010-12-23 | 2015-06-26 | Pfizer | Glucagon receptor modulators |
JP2014510105A (ja) | 2011-03-22 | 2014-04-24 | アムジエン・インコーポレーテツド | Pim阻害剤としてのアゾール化合物 |
US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
CA2868507A1 (en) | 2012-04-02 | 2013-10-10 | Cytokinetics, Inc. | Methods for improving diaphragm function |
SG11201406359TA (en) | 2012-04-11 | 2014-11-27 | Cytokinetics Inc | Improving resistance to skeletal muscle fatigue |
DK3137622T3 (da) | 2014-04-29 | 2022-02-07 | Cytokinetics Inc | Fremgangsmåder til at reducere tilbagegang af vitalkapacitet |
ES2750751T3 (es) * | 2014-09-09 | 2020-03-27 | Astellas Pharma Inc | Composición farmacéutica novedosa para la prevención y/o el tratamiento de la incontinencia urinaria |
-
2011
- 2011-04-20 AR ARP110101386A patent/AR081331A1/es active IP Right Grant
- 2011-04-22 KR KR1020127029536A patent/KR101781484B1/ko active IP Right Grant
- 2011-04-22 ME MEP-2016-137A patent/ME02439B/me unknown
- 2011-04-22 NZ NZ603594A patent/NZ603594A/en unknown
- 2011-04-22 CA CA2796637A patent/CA2796637C/en active Active
- 2011-04-22 WO PCT/US2011/033614 patent/WO2011133888A1/en active Application Filing
- 2011-04-22 PH PH12016502037A patent/PH12016502037A1/en unknown
- 2011-04-22 EA EA201201378A patent/EA028079B1/ru unknown
- 2011-04-22 LT LTEP16164963.7T patent/LT3127540T/lt unknown
- 2011-04-22 EP EP20153402.1A patent/EP3698795A1/en active Pending
- 2011-04-22 MY MYPI2017000156A patent/MY193277A/en unknown
- 2011-04-22 US US13/642,206 patent/US8962632B2/en active Active
- 2011-04-22 EA EA201700230A patent/EA037350B1/ru not_active IP Right Cessation
- 2011-04-22 HU HUE16164963A patent/HUE048815T2/hu unknown
- 2011-04-22 ES ES11772782.6T patent/ES2586302T3/es active Active
- 2011-04-22 ES ES16164963T patent/ES2784279T3/es active Active
- 2011-04-22 PT PT117727826T patent/PT2560653T/pt unknown
- 2011-04-22 RS RS20200376A patent/RS60137B1/sr unknown
- 2011-04-22 SI SI201131854T patent/SI3127540T1/sl unknown
- 2011-04-22 JP JP2013506329A patent/JP5852099B2/ja active Active
- 2011-04-22 TW TW100113963A patent/TWI520737B/zh active
- 2011-04-22 AU AU2011242575A patent/AU2011242575C1/en active Active
- 2011-04-22 KR KR1020177026330A patent/KR102003030B1/ko active IP Right Grant
- 2011-04-22 RS RS20160554A patent/RS54948B1/sr unknown
- 2011-04-22 LT LTEP11772782.6T patent/LT2560653T/lt unknown
- 2011-04-22 SG SG2012078002A patent/SG184959A1/en unknown
- 2011-04-22 PT PT161649637T patent/PT3127540T/pt unknown
- 2011-04-22 CN CN201610048645.1A patent/CN105712974B/zh active Active
- 2011-04-22 SI SI201130887A patent/SI2560653T1/sl unknown
- 2011-04-22 BR BR112012026951-8A patent/BR112012026951B1/pt active IP Right Grant
- 2011-04-22 EP EP11772782.6A patent/EP2560653B1/en active Active
- 2011-04-22 EP EP16164963.7A patent/EP3127540B1/en active Active
- 2011-04-22 MX MX2012012189A patent/MX2012012189A/es active IP Right Grant
- 2011-04-22 PL PL11772782.6T patent/PL2560653T3/pl unknown
- 2011-04-22 DK DK16164963.7T patent/DK3127540T3/da active
- 2011-04-22 DK DK11772782.6T patent/DK2560653T3/en active
- 2011-04-22 PL PL16164963T patent/PL3127540T3/pl unknown
- 2011-04-22 CN CN202010640406.1A patent/CN112047926A/zh active Pending
- 2011-04-22 CN CN201180021468.3A patent/CN103025331B/zh active Active
- 2011-04-22 MY MYPI2012004643A patent/MY163498A/en unknown
- 2011-04-22 HU HUE11772782A patent/HUE028953T2/en unknown
- 2011-04-22 ME MEP-2020-68A patent/ME03766B/me unknown
-
2012
- 2012-10-15 IL IL222467A patent/IL222467A/en active IP Right Grant
- 2012-10-22 CL CL2012002944A patent/CL2012002944A1/es unknown
- 2012-10-24 CO CO12189881A patent/CO6620055A2/es active IP Right Grant
- 2012-11-09 EC ECSP12012293 patent/ECSP12012293A/es unknown
-
2013
- 2013-07-09 HK HK13107992.8A patent/HK1180604A1/zh unknown
-
2014
- 2014-03-20 US US14/220,252 patent/US9018223B2/en active Active
-
2015
- 2015-01-12 US US14/594,315 patent/US9730886B2/en active Active
-
2016
- 2016-07-08 HR HRP20160827TT patent/HRP20160827T1/hr unknown
- 2016-07-12 SM SM201600226T patent/SMT201600226B/it unknown
- 2016-07-12 CY CY20161100664T patent/CY1117809T1/el unknown
- 2016-12-20 HK HK16114454A patent/HK1226068A1/zh unknown
-
2017
- 2017-07-10 US US15/645,977 patent/US10272030B2/en active Active
- 2017-08-07 IL IL253870A patent/IL253870B/en active IP Right Grant
-
2019
- 2019-03-13 US US16/352,626 patent/US10765624B2/en active Active
-
2020
- 2020-04-03 HR HRP20200549TT patent/HRP20200549T1/hr unknown
- 2020-04-14 CY CY20201100347T patent/CY1122944T1/el unknown
- 2020-07-28 US US16/941,079 patent/US11369565B2/en active Active
-
2022
- 2022-05-20 US US17/750,090 patent/US20230026651A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR081331A1 (es) | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos | |
AR081626A1 (es) | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos | |
ES2528451T3 (es) | Inhibidores de esfingosina cinasa | |
AR057131A1 (es) | Derivados de purina como inmunomodulador | |
AR052903A1 (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno. | |
AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
ECSP11011200A (es) | Derivados de oxadiazale como agonista de los receptores s1p1 | |
AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR059184A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica | |
AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
AR060658A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
AR081387A1 (es) | Derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta 2 y como antagonistas muscarinicos m3, composiciones farmaceuticas y uso de los mismos. | |
AR070458A1 (es) | Derivados de oxazolidina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de una infeccion bacteriana. | |
AR061642A1 (es) | Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas | |
AR059726A1 (es) | Moduladores de 11 beta hidroxil esteroide deshidrogenasa de tipo 1, composiciones farmaceuticas de los mismos, y metodos de uso de los mismos | |
AR056892A1 (es) | Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa | |
AR086538A1 (es) | COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE | |
NI200900037A (es) | Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica. | |
AR078542A1 (es) | Moduladores de gpr40 de pirrolidina | |
AR072227A1 (es) | Derivados de triazinona sustituidos | |
AR085489A1 (es) | Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias | |
AR091022A1 (es) | Inhibidores del nampt | |
ECSP11010901A (es) | Compuestos de amida útiles en terapia | |
HN2005000370A (es) | Derivados de pirido-pirimidina, su preparacion y su aplicacion en terapeutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |